Cite
Dickson AL, Daniel LL, Zanussi J, et al. TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results. Clin Pharmacol Ther. 2021;111(1):263-271doi: 10.1002/cpt.2428.
Dickson, A. L., Daniel, L. L., Zanussi, J., Dale Plummer, W., Wei, W. Q., Liu, G., Reese, T., Anandi, P., Birdwell, K. A., Kawai, V., Cox, N. J., Dupont, W. D., Hung, A. M., Feng, Q., Stein, C. M., & Chung, C. P. (2022). TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results. Clinical pharmacology and therapeutics, 111(1), 263-271. https://doi.org/10.1002/cpt.2428
Dickson, Alyson L, et al. "TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results." Clinical pharmacology and therapeutics vol. 111,1 (2022): 263-271. doi: https://doi.org/10.1002/cpt.2428
Dickson AL, Daniel LL, Zanussi J, Dale Plummer W, Wei WQ, Liu G, Reese T, Anandi P, Birdwell KA, Kawai V, Cox NJ, Dupont WD, Hung AM, Feng Q, Stein CM, Chung CP. TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results. Clin Pharmacol Ther. 2022 Jan;111(1):263-271. doi: 10.1002/cpt.2428. Epub 2021 Oct 12. PMID: 34582038; PMCID: PMC8678305.
Copy
Download .nbib